Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 308

1.

N-glycosylation of Rim21 at an Unconventional Site Fine-tunes Its Behavior in the Plasma Membrane.

Obara K, Kotani T, Nakatogawa H, Kihara A, Kamura T.

Cell Struct Funct. 2020 Jan 11;45(1):1-8. doi: 10.1247/csf.19021. Epub 2019 Nov 30.

2.

Hepatic Sdf2l1 controls feeding-induced ER stress and regulates metabolism.

Sasako T, Ohsugi M, Kubota N, Itoh S, Okazaki Y, Terai A, Kubota T, Yamashita S, Nakatsukasa K, Kamura T, Iwayama K, Tokuyama K, Kiyonari H, Furuta Y, Shibahara J, Fukayama M, Enooku K, Okushin K, Tsutsumi T, Tateishi R, Tobe K, Asahara H, Koike K, Kadowaki T, Ueki K.

Nat Commun. 2019 Feb 27;10(1):947. doi: 10.1038/s41467-019-08591-6.

3.

Analysis of gastric-type mucinous carcinoma of the uterine cervix - An aggressive tumor with a poor prognosis: A multi-institutional study.

Nishio S, Mikami Y, Tokunaga H, Yaegashi N, Satoh T, Saito M, Okamoto A, Kasamatsu T, Miyamoto T, Shiozawa T, Yoshioka Y, Mandai M, Kojima A, Takehara K, Kaneki E, Kobayashi H, Kaku T, Ushijima K, Kamura T.

Gynecol Oncol. 2019 Apr;153(1):13-19. doi: 10.1016/j.ygyno.2019.01.022. Epub 2019 Jan 29.

4.

Race and nodal disease status are prognostic factors in patients with stage IVB cervical cancer.

Nishio S, Matsuo K, Yonemoto K, Shimokawa M, Hosaka M, Kodama M, Miyake TM, Ushijima K, Kamura T, Westin SN, Soliman PT, Coleman RL.

Oncotarget. 2018 Aug 17;9(64):32321-32330. doi: 10.18632/oncotarget.25962. eCollection 2018 Aug 17.

5.

Phase III study of cisplatin with or without S-1 in patients with stage IVB, recurrent, or persistent cervical cancer.

Aoki Y, Ochiai K, Lim S, Aoki D, Kamiura S, Lin H, Katsumata N, Cha SD, Kim JH, Kim BG, Hirashima Y, Fujiwara K, Kim YT, Kim SM, Chung HH, Chang TC, Kamura T, Takizawa K, Takeuchi M, Kang SB.

Br J Cancer. 2018 Aug;119(5):530-537. doi: 10.1038/s41416-018-0206-7. Epub 2018 Aug 3.

6.

Insulin-like growth factor 1 receptor stabilizes the ETV6-NTRK3 chimeric oncoprotein by blocking its KPC1/Rnf123-mediated proteasomal degradation.

Tognon CE, Rafn B, Cetinbas NM, Kamura T, Trigo G, Rotblat B, Okumura F, Matsumoto M, Chow C, Davare M, Pollak M, Mayor T, Sorensen PH.

J Biol Chem. 2018 Aug 10;293(32):12502-12515. doi: 10.1074/jbc.RA117.000321. Epub 2018 Jun 14.

7.

The HECT-type ubiquitin ligase Tom1 contributes to the turnover of Spo12, a component of the FEAR network, in G2/M phase.

Nakatsukasa K, Sone M, Alemayehu DH, Okumura F, Kamura T.

FEBS Lett. 2018 May;592(10):1716-1724. doi: 10.1002/1873-3468.13066. Epub 2018 May 7.

8.

Ubiquitin ligase SPSB4 diminishes cell repulsive responses mediated by EphB2.

Okumura F, Joo-Okumura A, Obara K, Petersen A, Nishikimi A, Fukui Y, Nakatsukasa K, Kamura T.

Mol Biol Cell. 2017 Nov 15;28(24):3532-3541. doi: 10.1091/mbc.E17-07-0450. Epub 2017 Sep 20.

9.

Adults of Lasioderma serricorne and Stegobium paniceum (Anobiidae: Coleoptera) Are Attracted to Ultraviolet (UV) Over Blue Light LEDs.

Hironaka M, Kamura T, Osada M, Sasaki R, Shinoda K, Hariyama T, Miyatake T.

J Econ Entomol. 2017 Aug 1;110(4):1911-1915. doi: 10.1093/jee/tox127.

PMID:
28498915
10.

Enhancement of humoral and cell mediated immune response to HPV16 L1-derived peptides subsequent to vaccination with prophylactic bivalent HPV L1 virus-like particle vaccine in healthy females.

Yokomine M, Matsueda S, Kawano K, Sasada T, Fukui A, Yamashita T, Komatsu N, Shichijo S, Tasaki K, Matsukuma K, Itoh K, Kamura T, Ushijima K.

Exp Ther Med. 2017 Apr;13(4):1500-1505. doi: 10.3892/etm.2017.4150. Epub 2017 Feb 21.

11.

Hypoxia-inducible factor-2α stabilizes the von Hippel-Lindau (VHL) disease suppressor, Myb-related protein 2.

Okumura F, Joo-Okumura A, Nakatsukasa K, Kamura T.

PLoS One. 2017 Apr 10;12(4):e0175593. doi: 10.1371/journal.pone.0175593. eCollection 2017.

12.

Breakthrough chemotherapy-induced nausea and vomiting: report of a nationwide survey by the CINV Study Group of Japan.

Tamura K, Aiba K, Saeki T, Nakanishi Y, Kamura T, Baba H, Yoshida K, Yamamoto N, Kitagawa Y, Maehara Y, Shimokawa M, Hirata K, Kitajima M; CINV Study Group of Japan.

Int J Clin Oncol. 2017 Apr;22(2):405-412. doi: 10.1007/s10147-016-1069-7. Epub 2016 Dec 1.

PMID:
27909835
13.

Monitoring and Detecting the Cigarette Beetle (Coleoptera: Anobiidae) Using Ultraviolet (LED) Direct and Reflected Lights and/or Pheromone Traps in a Laboratory and a Storehouse.

Miyatake T, Yokoi T, Fuchikawa T, Korehisa N, Kamura T, Nanba K, Ryouji S, Kamioka N, Hironaka M, Osada M, Hariyama T, Sasaki R, Shinoda K.

J Econ Entomol. 2016 Dec 1;109(6):2551-2560. doi: 10.1093/jee/tow225.

PMID:
27760785
14.

ASB7 regulates spindle dynamics and genome integrity by targeting DDA3 for proteasomal degradation.

Uematsu K, Okumura F, Tonogai S, Joo-Okumura A, Alemayehu DH, Nishikimi A, Fukui Y, Nakatsukasa K, Kamura T.

J Cell Biol. 2016 Oct 10;215(1):95-106. Epub 2016 Oct 3.

15.

Prognostic factors from a randomized phase III trial of paclitaxel and carboplatin versus paclitaxel and cisplatin in metastatic or recurrent cervical cancer: Japan Clinical Oncology Group (JCOG) trial: JCOG0505-S1.

Nishio S, Kitagawa R, Shibata T, Yoshikawa H, Konishi I, Ushijima K, Kamura T.

Cancer Chemother Pharmacol. 2016 Oct;78(4):785-90. doi: 10.1007/s00280-016-3133-4. Epub 2016 Aug 23.

PMID:
27553435
16.

Comparison of treatment invasiveness between upfront debulking surgery versus interval debulking surgery following neoadjuvant chemotherapy for stage III/IV ovarian, tubal, and peritoneal cancers in a phase III randomised trial: Japan Clinical Oncology Group Study JCOG0602.

Onda T, Satoh T, Saito T, Kasamatsu T, Nakanishi T, Nakamura K, Wakabayashi M, Takehara K, Saito M, Ushijima K, Kobayashi H, Kawana K, Yokota H, Takano M, Takeshima N, Watanabe Y, Yaegashi N, Konishi I, Kamura T, Yoshikawa H; Japan Clinical Oncology Group.

Eur J Cancer. 2016 Sep;64:22-31. doi: 10.1016/j.ejca.2016.05.017. Epub 2016 Jun 17.

PMID:
27323348
17.

Parallel Regulation of von Hippel-Lindau Disease by pVHL-Mediated Degradation of B-Myb and Hypoxia-Inducible Factor α.

Okumura F, Uematsu K, Byrne SD, Hirano M, Joo-Okumura A, Nishikimi A, Shuin T, Fukui Y, Nakatsukasa K, Kamura T.

Mol Cell Biol. 2016 May 31;36(12):1803-17. doi: 10.1128/MCB.00067-16. Print 2016 Jun 15.

18.

The role of cullin 5-containing ubiquitin ligases.

Okumura F, Joo-Okumura A, Nakatsukasa K, Kamura T.

Cell Div. 2016 Mar 9;11:1. doi: 10.1186/s13008-016-0016-3. eCollection 2016. Review.

19.

Subcellular Fractionation Analysis of the Extraction of Ubiquitinated Polytopic Membrane Substrate during ER-Associated Degradation.

Nakatsukasa K, Kamura T.

PLoS One. 2016 Feb 5;11(2):e0148327. doi: 10.1371/journal.pone.0148327. eCollection 2016.

20.

A prospective observational study on chemotherapy-induced nausea and vomiting (CINV) in patients with gynecologic cancer by the CINV Study Group of Japan.

Mizuno M, Hiura M, Kikkawa F, Numa F, Yaegashi N, Narahara H, Aoki D, Kimura E, Kato H, Shimokawa M, Sugiyama T, Kamura T.

Gynecol Oncol. 2016 Mar;140(3):559-64. doi: 10.1016/j.ygyno.2015.12.029. Epub 2015 Dec 31.

PMID:
26748216
21.

Proteolytic regulation of metabolic enzymes by E3 ubiquitin ligase complexes: lessons from yeast.

Nakatsukasa K, Okumura F, Kamura T.

Crit Rev Biochem Mol Biol. 2015;50(6):489-502. doi: 10.3109/10409238.2015.1081869. Epub 2015 Sep 11. Review.

PMID:
26362128
22.

Personalized peptide vaccination for cervical cancer patients who have received prior platinum-based chemotherapy.

Kawano K, Tsuda N, Waki K, Matsueda S, Hata Y, Ushijima K, Itoh K, Yamada A, Kamura T.

Cancer Sci. 2015 Sep;106(9):1111-7. doi: 10.1111/cas.12729. Epub 2015 Jul 22.

23.

Assessment of MR Imaging as a Tool to Differentiate between the Major Histological Types of Uterine Sarcomas.

Sumi A, Terasaki H, Sanada S, Uchida M, Tomioka Y, Kamura T, Yano H, Abe T.

Magn Reson Med Sci. 2015;14(4):295-304. doi: 10.2463/mrms.2014-0023. Epub 2015 Jun 23.

24.

The Ubiquitin Ligase SCF(Ucc1) Acts as a Metabolic Switch for the Glyoxylate Cycle.

Nakatsukasa K, Nishimura T, Byrne SD, Okamoto M, Takahashi-Nakaguchi A, Chibana H, Okumura F, Kamura T.

Mol Cell. 2015 Jul 2;59(1):22-34. doi: 10.1016/j.molcel.2015.04.013. Epub 2015 May 14.

25.

Assessment of 99mTc-MIBI SPECT(/CT) to monitor multidrug resistance-related proteins and apoptosis-related proteins in patients with ovarian cancer: a preliminary study.

Kurata S, Ushijima K, Kawahara A, Kaida H, Kawano K, Hirose Y, Kage M, Kamura T, Ishibashi M, Abe T.

Ann Nucl Med. 2015 Aug;29(7):643-9. doi: 10.1007/s12149-015-0980-8. Epub 2015 Apr 29.

PMID:
25921216
26.

Prognosis of Pregnant Women with One Abnormal Value on 75g OGTT.

Kozuma Y, Inoue S, Horinouchi T, Shinagawa T, Nakayama H, Kawaguchi A, Hori D, Kamura T, Yamada K, Ushijima K.

Kurume Med J. 2015;61(3-4):59-64. doi: 10.2739/kurumemedj.MS65001. Epub 2015 Mar 25.

27.

Phosphorylation of p27Kip1 on serine 10 is required for its binding to CRM1 and nuclear export.

Ishida N, Hara T, Kamura T, Yoshida M, Nakayama K, Nakayama KI.

J Biol Chem. 2015 Mar 13;290(11):6754. doi: 10.1074/jbc.A114.100762. No abstract available.

28.

Paclitaxel Plus Carboplatin Versus Paclitaxel Plus Cisplatin in Metastatic or Recurrent Cervical Cancer: The Open-Label Randomized Phase III Trial JCOG0505.

Kitagawa R, Katsumata N, Shibata T, Kamura T, Kasamatsu T, Nakanishi T, Nishimura S, Ushijima K, Takano M, Satoh T, Yoshikawa H.

J Clin Oncol. 2015 Jul 1;33(19):2129-35. doi: 10.1200/JCO.2014.58.4391. Epub 2015 Mar 2.

PMID:
25732161
29.

Testing the effectiveness of antiemetic guidelines: results of a prospective registry by the CINV Study Group of Japan.

Tamura K, Aiba K, Saeki T, Nakanishi Y, Kamura T, Baba H, Yoshida K, Yamamoto N, Kitagawa Y, Maehara Y, Shimokawa M, Hirata K, Kitajima M; CINV Study Group of Japan.

Int J Clin Oncol. 2015 Oct;20(5):855-65. doi: 10.1007/s10147-015-0786-7. Epub 2015 Feb 15.

PMID:
25681876
30.

Clinical tumor diameter and prognosis of patients with FIGO stage IB1 cervical cancer (JCOG0806-A).

Kato T, Takashima A, Kasamatsu T, Nakamura K, Mizusawa J, Nakanishi T, Takeshima N, Kamiura S, Onda T, Sumi T, Takano M, Nakai H, Saito T, Fujiwara K, Yokoyama M, Itamochi H, Takehara K, Yokota H, Mizunoe T, Takeda S, Sonoda K, Shiozawa T, Kawabata T, Honma S, Fukuda H, Yaegashi N, Yoshikawa H, Konishi I, Kamura T; Gynecologic Oncology Study Group of the Japan Clinical Oncology Group.

Gynecol Oncol. 2015 Apr;137(1):34-9. doi: 10.1016/j.ygyno.2015.01.548. Epub 2015 Feb 7.

PMID:
25662625
31.

Administration of standard-dose BEP regimen (bleomycin+etoposide+cisplatin) is essential for treatment of ovarian yolk sac tumour.

Satoh T, Aoki Y, Kasamatsu T, Ochiai K, Takano M, Watanabe Y, Kikkawa F, Takeshima N, Hatae M, Yokota H, Saito T, Yaegashi N, Kobayashi H, Baba T, Kodama S, Saito T, Sakuragi N, Sumi T, Kamura T, Yoshikawa H.

Eur J Cancer. 2015 Feb;51(3):340-51. doi: 10.1016/j.ejca.2014.12.004. Epub 2015 Jan 2.

PMID:
25559616
32.

Rare allele of a previously unidentified histone H4 acetyltransferase enhances grain weight, yield, and plant biomass in rice.

Song XJ, Kuroha T, Ayano M, Furuta T, Nagai K, Komeda N, Segami S, Miura K, Ogawa D, Kamura T, Suzuki T, Higashiyama T, Yamasaki M, Mori H, Inukai Y, Wu J, Kitano H, Sakakibara H, Jacobsen SE, Ashikari M.

Proc Natl Acad Sci U S A. 2015 Jan 6;112(1):76-81. doi: 10.1073/pnas.1421127112. Epub 2014 Dec 22.

33.

Radiation effects on DNA content of cervical cancer cells: A rapid evaluation of radiation sensitivity by laser scanning cytometry.

Fujiyoshi N, Ushijima K, Kawano K, Fujiyoshi K, Yamaguchi T, Araki Y, Kakuma T, Watanabe S, Kaku T, Nishida T, Kamura T.

Mol Clin Oncol. 2015 Jan;3(1):51-54. Epub 2014 Sep 9.

34.

Phase II trial of oral etoposide plus intravenous irinotecan in patients with platinum-resistant and taxane-pretreated ovarian cancer (JCOG0503).

Matsumoto K, Katsumata N, Shibata T, Satoh T, Saitou M, Yunokawa M, Takano T, Nakamura K, Kamura T, Konishi I.

Gynecol Oncol. 2015 Feb;136(2):218-23. doi: 10.1016/j.ygyno.2014.10.026. Epub 2014 Oct 31.

PMID:
25449313
35.

Changes in the nitric oxide-soluble guanylate cyclase system and natriuretic peptide receptor system in placentas of pregnant Dahl salt-sensitive rats.

Takushima S, Nishi Y, Nonoshita A, Mifune H, Hirata R, Tanaka E, Doi R, Hori D, Kamura T, Ushijima K.

J Obstet Gynaecol Res. 2015 Apr;41(4):540-50. doi: 10.1111/jog.12602. Epub 2014 Nov 5.

PMID:
25370989
36.

Non-randomized confirmatory trial of modified radical hysterectomy for patients with tumor diameter 2 cm or less FIGO Stage IB1 uterine cervical cancer: Japan Clinical Oncology Group Study (JCOG1101).

Kunieda F, Kasamatsu T, Arimoto T, Onda T, Toita T, Shibata T, Fukuda H, Kamura T; Gynecologic Cancer Study Group of the Japan Clinical Oncology Group.

Jpn J Clin Oncol. 2015 Jan;45(1):123-6. doi: 10.1093/jjco/hyu168. Epub 2014 Nov 2.

PMID:
25368103
37.

Prevention of lymphocele development in gynecologic cancers by the electrothermal bipolar vessel sealing device.

Tsuda N, Ushijima K, Kawano K, Takemoto S, Nishio S, Sonoda G, Kamura T.

J Gynecol Oncol. 2014 Jul;25(3):229-35. doi: 10.3802/jgo.2014.25.3.229. Epub 2014 Jul 3.

38.

The nutrient stress-induced small GTPase Rab5 contributes to the activation of vesicle trafficking and vacuolar activity.

Nakatsukasa K, Kanada A, Matsuzaki M, Byrne SD, Okumura F, Kamura T.

J Biol Chem. 2014 Jul 25;289(30):20970-8.

39.

Recent technical developments in the study of ER-associated degradation.

Nakatsukasa K, Kamura T, Brodsky JL.

Curr Opin Cell Biol. 2014 Aug;29:82-91. doi: 10.1016/j.ceb.2014.04.008. Epub 2014 May 24. Review.

40.

Cytological nuclear atypia classification can predict prognosis in patients with endometrial cancer.

Yamaguchi T, Kawahara A, Hattori S, Taira T, Abe H, Sanada S, Akiba J, Nishio S, Ushijima K, Kamura T, Kage M.

Cytopathology. 2015 Jun;26(3):157-66. doi: 10.1111/cyt.12149. Epub 2014 May 14.

PMID:
24827996
41.

Feasibility study of personalized peptide vaccination for recurrent ovarian cancer patients.

Kawano K, Tsuda N, Matsueda S, Sasada T, Watanabe N, Ushijima K, Yamaguchi T, Yokomine M, Itoh K, Yamada A, Kamura T.

Immunopharmacol Immunotoxicol. 2014 Jun;36(3):224-36. doi: 10.3109/08923973.2014.913617. Epub 2014 Apr 29.

PMID:
24773550
42.

Nuclear Y-box-binding protein-1 is a poor prognostic marker and related to epidermal growth factor receptor in uterine cervical cancer.

Nishio S, Ushijima K, Yamaguchi T, Sasajima Y, Tsuda H, Kasamatsu T, Kage M, Ono M, Kuwano M, Kamura T.

Gynecol Oncol. 2014 Mar;132(3):703-8. doi: 10.1016/j.ygyno.2014.01.045. Epub 2014 Jan 31.

PMID:
24486603
43.

[Safety and efficacy of pegylated liposomal Doxorubicin and Carboplatin on platinum-sensitive recurrent epithelial ovarian cancer].

Nishio S, Ushijima K, Shimizu T, Tachibana T, Nasu H, Aiko K, Kawano R, Kurokawa Y, Sumino Y, Yokomine M, Takemoto S, Kamura T.

Gan To Kagaku Ryoho. 2013 Dec;40(13):2539-43. Japanese.

PMID:
24335366
44.

Validity of intraoperative diagnosis at laparoscopic surgery for ovarian tumors.

Takemoto S, Ushijima K, Kawano R, Fukui A, Terada A, Fujimoto T, Imaishi H, Kamura T.

J Minim Invasive Gynecol. 2014 Jul-Aug;21(4):576-9. doi: 10.1016/j.jmig.2013.12.002. Epub 2013 Dec 10.

PMID:
24333631
45.

[A patient with recurrent ovarian clear cell adenocarcinoma and chronic kidney disease exhibited complete response to paclitaxel plus carboplatin].

Muto M, Nishio S, Takemoto S, Ota S, Sonoda G, Ushijima K, Kamura T.

Gan To Kagaku Ryoho. 2013 Oct;40(10):1419-21. Japanese.

PMID:
24196084
46.

Status of treatment for the overall population of patients with stage IVb endometrial cancer, and evaluation of the role of preoperative chemotherapy: a retrospective multi-institutional study of 426 patients in Japan.

Eto T, Saito T, Shimokawa M, Hatae M, Takeshima N, Kobayashi H, Kasamatsu T, Yoshikawa H, Kamura T, Konishi I.

Gynecol Oncol. 2013 Dec;131(3):574-80. doi: 10.1016/j.ygyno.2013.08.036. Epub 2013 Sep 7.

PMID:
24016406
47.

RECQL1 DNA repair helicase: a potential therapeutic target and a proliferative marker against ovarian cancer.

Sanada S, Futami K, Terada A, Yonemoto K, Ogasawara S, Akiba J, Yasumoto M, Sumi A, Ushijima K, Kamura T, Furuichi Y, Yano H.

PLoS One. 2013 Aug 9;8(8):e72820. doi: 10.1371/journal.pone.0072820. eCollection 2013.

48.

Chemotherapy for advanced or recurrent cervical cancer.

Kamura T, Ushijima K.

Taiwan J Obstet Gynecol. 2013 Jun;52(2):161-4. doi: 10.1016/j.tjog.2013.04.003. Review.

49.

Integrated molecular analysis of clear-cell renal cell carcinoma.

Sato Y, Yoshizato T, Shiraishi Y, Maekawa S, Okuno Y, Kamura T, Shimamura T, Sato-Otsubo A, Nagae G, Suzuki H, Nagata Y, Yoshida K, Kon A, Suzuki Y, Chiba K, Tanaka H, Niida A, Fujimoto A, Tsunoda T, Morikawa T, Maeda D, Kume H, Sugano S, Fukayama M, Aburatani H, Sanada M, Miyano S, Homma Y, Ogawa S.

Nat Genet. 2013 Aug;45(8):860-7. doi: 10.1038/ng.2699. Epub 2013 Jun 24.

PMID:
23797736
50.

Concurrent chemoradiotherapy with low-dose daily cisplatin for high risk uterine cervical cancer: a long-term follow-up study.

Ushijima K, Fujiyoshi K, Kawano K, Tsuda N, Nishio S, Eto H, Kamura T.

J Gynecol Oncol. 2013 Apr;24(2):108-13. doi: 10.3802/jgo.2013.24.2.108. Epub 2013 Apr 5.

Supplemental Content

Loading ...
Support Center